Latest Articles
Aspira Women's Health Receives Approval from New York State Department of Health for OvaWatch® - The Manila Times
Aspira Women's Health Receives Approval from New York State Department of Health for OvaWatch® The Manila Times
Published: Oct. 15, 2024, 8:23 p.m.
Japan Hysteroscopic Planing System Market By Application - thirdeyenews.in
Japan Hysteroscopic Planing System Market By Application thirdeyenews.in
Published: Oct. 14, 2024, 3:02 p.m.
Japan Hysteroscopic Planing System Market By Application - Third Eye News
Japan Hysteroscopic Planing System Market By Application Third Eye News
Published: Oct. 14, 2024, 3:02 p.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive
Published: July 1, 2024, 7 a.m.
Unwrapping a revolution in female health testing: Will we finally get the answers and support we need? - Women's Health UK
Unwrapping a revolution in female health testing: Will we finally get the answers and support we need? Women's Health UK
Published: July 1, 2024, 7 a.m.
Warning after scam QR codes appear in car parks - BBC.com
Warning after scam QR codes appear in car parks BBC.com
Published: June 28, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!